Opendata, web and dolomites


Immune Monitoring for RIsk STratification in Solid Organ Transplant Recipients

Total Cost €


EC-Contrib. €






 ImMoRiSt project word cloud

Explore the words cloud of the ImMoRiSt project. It provides you a very rough idea of what is the project "ImMoRiSt" about.

infections    obtain    competitor    immune    sot    cell    gamma    lung    immunosuppressive    interferon    yield    right    strength    solid    market    relatively    switzerland    setting    recipients    complications    selectively    provides    business    germany    leader    organ    grow    kidney    performed    mediated    firm    transplant    immunomonitoring    pursued    heart    biomarker    scan    final    strategy    ivd    centers    operate    improves    diagnostic    monitoring    freedom    transplantation    validate    plan    clinical    ce    quantitative    entry    patients    physicians    biosciences    place    ifn    every    function    links    stimulants    transplanted    tests    global    proprietary    triggered    caused    approval    detection    logical    lophius    stimulate    validation    outcome    frequency    feasibility    release    patient    suited    liver    austria    blood    clinically    24    marking    rejection    highest    obtaining    parallel    cells    regulatory    dosage    functional    uses    qualitative    explore    cocktail    drugs   

Project "ImMoRiSt" data sheet

The following table provides information about the project.


Organization address
address: AM BIOPARK 13
postcode: 93053
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Every year ~ 40.000 patients throughout the EU are transplanted a new kidney, lung, liver, heart or another organ. The frequency of clinical complications is relatively high because at present there are no diagnostic tests that help physicians to determine the right dosage of immunosuppressive drugs necessary to avoid both organ rejection and clinical complications caused by infections.

Lophius Biosciences GmbH has developed I-Scan, a functional immune monitoring test that within 24 h provides important information on the strength of the immune system in solid organ transplant recipients. I-Scan uses a proprietary cocktail of stimulants that selectively stimulate the clinically relevant immune cells in a patient’s blood sample. The detection of the triggered interferon γ (IFN-γ) release provides a qualitative and quantitative measurement of cell-mediated immune function.

The feasibility study performed during Phase 1 will explore issues related to both, the clinical biomarker validation study and the best market entry strategy. Several objectives are pursued in parallel and encompass: • Setting up the business plan which includes a competitor as well as a freedom-to-operate analysis and a market entry strategy. • Selection of clinical study partners and defining the design of the clinical study, best suited to yield highest clinical evidence • Obtaining regulatory approval for the planned clinical study and setting a strategy to obtain regulatory approval / CE-Marking for final I-Scan products.

Lophius will apply for Phase 2 funding of a clinical study to validate that I-Scan improves the outcome of SOT patients. This study is likely to take place in Germany, Switzerland and Austria where Lophius has already established firm links to transplantation centers. The study is the logical next step to further grow Lophius to become a global leader in the IVD market for immunomonitoring

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMORIST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMORIST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More